PCSK9 INHIBITOR Overview
Upcoming Projects (PCSK9 INHIBITOR)
-
Don’t see a project related to the keyword you care about? Create your own!
Executed Projects (PCSK9 INHIBITOR)
-
Third View: Discussing Verve Therapeutics' Phase1B results for VERVE-102, an in vivo base editing medicine targeting PCSK9.
Ticker: VERV
Executed On: May 02, 2025 at 10:00 AM EDT -
Second View: Discussing Verve Therapeutics' Phase1B results for VERVE-102, an in vivo base editing medicine targeting PCSK9.
Ticker: VERV
Executed On: May 01, 2025 at 09:30 AM EDT -
Discussing Verve Therapeutics' Phase1B results for VERVE-102, an in vivo base editing medicine targeting PCSK9.
Ticker: VERV
Executed On: Apr 24, 2025 at 05:00 PM EDT -
A third look: Digging in to the Phase 2b data presented at the AAC Conference for Merck's oral PCSK9 inhibitor, MK-0616, in patients with hypercholesterolemia
Ticker: MRK
Executed On: Mar 14, 2023 at 07:00 PM EDT -
A second look: Digging in to the Phase 2b data presented at the AAC Conference for Merck's oral PCSK9 inhibitor, MK-0616, in patients with hypercholesterolemia
Ticker: MRK
Executed On: Mar 14, 2023 at 06:00 PM EDT -
Digging in to the Phase 2b data presented at the AAC Conference for Merck's oral PCSK9 inhibitor, MK-0616, in patients with hypercholesterolemia
Ticker: MRK
Executed On: Mar 13, 2023 at 04:00 PM EDT
Upcoming & Overdue Catalysts (PCSK9 INHIBITOR)
-
Don’t see a catalyst related to the keyword you care about? Create your own!
Strategic Initiatives (PCSK9 INHIBITOR)
-
Don’t see a strategic initiative related to the keyword you care about? Create your own!
